HIV preexposure prophylaxis treatment patterns in a national health plan population.

ABSTRACT:

Background

Medication nonadherence diminishes the benefits of preexposure prophylaxis (PrEP) for the 1.2 million Americans at risk for HIV exposure.

Objective

To describe HIV PrEP treatment patterns among Medicare Advantage Prescription Drug (MAPD) plan and commercially insured beneficiaries.

Methods

This retrospective cohort study identified patients aged 16 to 89 years with at least 1 dispensing of emtricitabine-tenofovir disoproxil fumarate from July 2012, through December 2020, or emtricitabine-tenofovir alafenamide from October 2019 through December 2020, and who were continuously enrolled at least 12 months prior to and following the earliest PrEP claim. Outcomes were HIV PrEP adherence measured by proportion of days covered (PDC) using 2 binary thresholds of 0.

SUBMITTER: Rastegar J 

PROVIDER: S-EPMC10776253 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature